Impact of bacterial eradication on the cell proliferation and p53 protein accumulation in Helicobacter pylori-associated gastritis

Anticancer Res. 2000 Mar-Apr;20(2B):1221-8.

Abstract

Background: This study investigates the cell proliferation and the expression of p53 protein in Helicobacter pylori (H. pylori)-associated gastritis and assesses the effect of bacterial eradication on these epithelial factors.

Material and methods: Seventy-nine patients with H. pylori-associated gastritis were randomized into the control group (n = 38) and anti-H. pylori group (n = 41). Each patient received endoscopic examinations with gastric biopsy before and 8 weeks after the treatment. The specimens from gastric antrum were immunostained for monoclonal antibodies against the proliferating cell nuclear antigen (PCNA) and p53 protein.

Results: In the control group, the total labeling index (L.I.) of PCNA and the positive index (P.I.) of p53 in the whole foveolar epithelium were unchanged after treatment. In the anti-H. pylori group, 35 of 41 cases (85.3%) achieved eradication of H. pylori. Amongst the H. pylori-eradicated cases, the total L.I. of PCNA in the whole foveolar epithelium did not meaningfully alter after H. pylori elimination (p > 0.05). However, a significant reduction of L.I. was observed in the middle compartments of the gastric pits (before vs. after treatment: 14.0 vs. 7.3, p < 0.05). With regard to the p53 expression, the P.I.s were significantly decreased in the whole foveolar epithelium (before vs. after treatment: 0.57 vs. 0.17, p < 0.05) and in each compartment of the gastric pits (before vs. after treatment: [upper compartment]: 0.34 vs. 0.15, p < 0.05; [middle compartment]: 0.67 vs. 0.23, p < 0.05; [lower compartment]: 0.71 vs. 0.20, p < 0.05) after eradication of H. pylori.

Conclusions: Bacterial eradication reverses the hyperproliferating status of the foveolar epithelium in patients with H. pylori gastritis and leads to a decrease in p53 accumulation in the epithelial cells.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Antacids / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Atrophy
  • Cell Division
  • Drug Therapy, Combination / therapeutic use*
  • Female
  • Gastritis / drug therapy*
  • Gastritis / microbiology
  • Gastritis / pathology*
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / pathology*
  • Helicobacter pylori*
  • Humans
  • Immunohistochemistry
  • Lansoprazole
  • Male
  • Metaplasia
  • Metronidazole / therapeutic use*
  • Middle Aged
  • Omeprazole / analogs & derivatives*
  • Omeprazole / therapeutic use
  • Organometallic Compounds / therapeutic use
  • Proliferating Cell Nuclear Antigen / analysis
  • Tetracycline / therapeutic use*
  • Tumor Suppressor Protein p53 / analysis*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Antacids
  • Anti-Bacterial Agents
  • Organometallic Compounds
  • Proliferating Cell Nuclear Antigen
  • Tumor Suppressor Protein p53
  • Lansoprazole
  • Metronidazole
  • Tetracycline
  • bismuth tripotassium dicitrate
  • Omeprazole